Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15817 | 0.84 | ALOX5 (0.61) | MAOBALOX5RAB9ASMN1; SMN2LMNA | |
| SCHEMBL17658995 | 0.81 | ALOX5 (0.58) | MAOBALOX5RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL31166954 | 0.81 | ALOX5 (0.58) | MAOBALOX5RAB9ASMN1; SMN2LMNA | |
| SCHEMBL27833075 | 0.80 | MAOB (0.44) | MAOBALOX5MEN1KMT2AMAOA | |
| SCHEMBL8597419 | 0.79 | MRGPRX4 (0.47) | MAOBMRGPRX4 | |
| SCHEMBL30065009 | 0.79 | MAOB (0.57) | MAOBALOX5RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7879365 | 0.79 | ALOX5 (0.56) | MAOBALOX5RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL29502845 | 0.79 | MAOB (0.58) | MAOBALOX5RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1532839 | 0.79 | LMNA (0.59) | MAOBALOX5RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL8251097 | 0.79 | MAOB (0.57) | MAOBALOX5RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101415691-B | Triazole derivatives | TAISHO PHARMACEUTICAL CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022091-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| CN-101415691-A | Triazole derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-1988083-A1 | TRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1988083-A1 | TRIAZOLE DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269960-A1 | TRIAZOLE DERIVATIVE | S1PR3, S1PR1, S1PR5 | MAOB 3395/4885ALOX5 1830/4885RAB9A 3263/4885 |
| US-20100041655-A1 | TRIAZOLE DERIVATIVE | S1PR3, S1PR1, S1PR5 | MAOB 3344/4885ALOX5 1680/4885RAB9A 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.